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Abstract—The reference standard CX-6258 {(E)-5-chloro-3-((5-(3-(4-methyl-1,4-diazepane-1-carbonyl)phenyl)furan-2-
yl)methylene)indolin-2-one, 4a} and its desmethylated precursor N-desmethyl-CX-6258 {(E)-3-((5-(3-(1,4-diazepane-1-
carbonyl)phenyl)furan-2-yl)methylene)-5-chloroindolin-2-one, 5} for radiolabeling were synthesized from 5-bromo-2-furaldehyde and 3-
carboxybenzeneboronic acid in 3 and 4 steps with 29-49% and 24-32% overall chemical yield, respectively. The target tracer [11C]CX-
6258 {(E)-5-chloro-3-((5-(3-(4-[11C]methyl-1,4-diazepane-1-carbonyl)phenyl)furan-2-yl)methylene)indolin-2-one, [11C]4a} was prepared 
from N-desmethyl-CX-6258 (5) with [11C]CH3OTf under basic condition (2 N NaOH) through N-[11C]methylation and isolated by HPLC 
combined with solid-phase extraction (SPE) in 40-50% radiochemical yield based on [11C]CO2 and decay corrected to end of 
bombardment (EOB) with 370-1110 GBq/µmol specific activity at EOB.   
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Pim kinases (Provirus Integration site for Moloney 
murine leukemia virus) are a family of serine/threonine 
kinases, including three different members Pim1, Pim2 
and Pim3.1-3 This family of kinases regulates signaling 
pathways via Janus kinase (JAK)/signal transducer and 
activator of transcription (STAT) pathway and plays 
pivotal roles in cancer development and progression.4-6 
Pim kinases including Pim1, Pim2 and Pim3 are 
overexpressed not only in hematologic malignancies but 
also in solid tumors, and have become an attractive 
targets for therapeutics in cancer.7-10 Many Pim kinases 
inhibitors have been discovered.11,12 Recently a potent, 
selective, and orally efficacious pan-Pim kinases 
inhibitor called CX-6258 has been developed by Cylene 
Pharmaceuticals, and the IC50 of CX-6258 is 5, 25, and 
16 nM for Pim1, Pim2, and Pim3, respectively.13    Pim 
kinases have also become a promising target for 
molecular imaging of Pim kinases-related cancers and 
image-guided therapy using the biomedical imaging 
technique positron emission tomography (PET). In our 
previous work, we have developed a series of 
radiolabeled (carbon-11 and fluorine-18) protein kinase 
(PK) inhibitors such as [11C]MKC-1 ([11C]Ro 31-7453), 
[11C]SB-216763, [11C]Enzastaurin ([11C]LY317615), 
[11C]GSK2126458, 2-[18F]GSK2126458 and 4-
[18F]GSK2126458, as shown in Figure 1, as new cancer 
imaging agents for PET to study PK and PK 
inhibitors.14-20 In this ongoing study, we target Pim 
kinases. Here we report the design, synthesis and 
labeling of [11C]CX-6258 (Figure 1).         
The reference standard CX-6258 {(E)-5-chloro-3-((5-
(3-(4-methyl-1,4-diazepane-1-carbonyl)phenyl)furan-2-
yl)methylene)indolin-2-one, 4a} and its [11C]-labeling 
precursor N-desmethyl-CX-6258 {(E)-3-((5-(3-(1,4-
diazepane-1-carbonyl)phenyl)furan-2-yl)methylene)-5-
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chloroindolin-2-one, 5} were prepared based on the 
reported method13 with modifications. As shown in 
Scheme 1, Suzuki cross-coupling of 3-
carboxybenzeneboronic acid with 5-bromo-2-
furaldehyde in the presence of aqueous 2 M Na2CO3 
using Pd(OAc)2 as catalyst in toluene/EtOH to give 3-
(5-formylfuran-2-yl)benzoic acid (1) in 89% yield.21 
Compounds 2a and 2b were achieved via amide bond 
coupling of acid 1 with homopiperazines in the presence 
of N,N-diisopropylethylamine (DIPEA) using O-
(benzotriazo-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate (HBTU) as coupling agent in N,N-
dimethylformamide (DMF) with 75% and 64% yield, 
respectively.22 Condensation of 5-chlorooxindole with 
aldehydes 2a and 2b using piperidine as catalyst in 
EtOH afforded standard compound 4a and N-Boc 
protected precursor 4b with 44% and 64% yield, 
respectively.23 Compounds 4a and 4b could be obtained 
by reverse the above two steps in much higher yields. 
Condensation of compound 1 with 5-chlorooxindole 
using piperidine as catalyst in EtOH to provide acid 3 in 
70% yield, which was coupled with homopiperazines 
using 1,1'-carbonyldimidazole (CDI) as coupling agent 
in DMF to provide 4a and 4b in 78% and 79% yield, 
respectively. The Boc group of 4b was removed with 
trifluoroacetic acid (TFA) in CH2Cl2 to afford the 
precursor 5 in 66% yield. 
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Figure 1. Radiolabeled PK inhibitors. 
 
Synthesis of the target tracer [11C]CX-6258 {(E)-5-
chloro-3-((5-(3-(4-[11C]methyl-1,4-diazepane-1-
carbonyl)phenyl)furan-2-yl)methylene)indolin-2-one, 
[11C]4a} is indicated in Scheme 2. The desmethylated 
precursor 5 was labeled by [11C]methyl triflate 
([11C]CH3OTf)24,25 through N-[11C]methylation26-28 at 80 
°C under basic condition (2 N NaOH) and isolated by a 
semi-preparative reverse-phase (RP) high performance 
liquid chromatography (HPLC) with a C-18 column and 
a solid-phase extraction (SPE) with a disposable C-18 
Plus Sep-Pak cartridge (a second purification or 
isolation process)29-31 to produce the corresponding pure 
radiolabeled compound [11C]4a in 40-50%  
radiochemical yield, decay corrected to end of 
bombardment (EOB), based on [11C]CO2. There are two 
nitrogen positions in the precursor 5 where the N-
[11C]methylation reaction could potentially happen. 
However, the reactivity for N-[11C]methylation is 
different between these two positions. The acidity of 
amine –NH is greater than amide –NH, thus the 
deprotonization at –NH of amine is easier than at –NH 
of amide under basic condition, the N-[11C]methylation 
reaction would prefer to occur at amine –NH, and the 
target tracer [11C]4a would be a major product. 
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Scheme 1. Synthesis of the reference standard CX-6258 (4a) and its 
precursor N-desmethyl-CX-6258 (5).  
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Scheme 2. Synthesis of the target tracer [11C]CX-6258. 
 
[11C]CH3OTf was used as the [11C]-radiolabeled 
precursor, which is more reactive than another 
commonly used [11C]-methylation reagent [11C]methyl 
iodide ([11C]CH3I)32, and thus, the radiochemical yield 
of [11C]4a was relatively higher. Basic condition would 
help the N-[11C]methylation of precursor and 
significantly increase the radiochemical yield of 
[11C]4a. Small amount of the precursor (0.3-0.5 mg) 
was used for radiolabeling instead of commonly used 
large amount of the precursor (1.0-1.5 mg), which 
improved the chemical purity of the final tracer 
solution. However, the small amount of precursor could 
potentially decrease the radiolabeling yield and increase 
the specific activity of the target tracer by decreasing 
the radiolabeling product as well as product mass. In 
addition, in order to make more product radioactivity, 
we also optimized the semi-preparative HPLC 
conditions including column, mobile phase and flow 
rate to shorten the retention time of [11C]4a to 8-9 min. 
Addition of NaHCO3 solution to quench the 
radiolabeling reaction and to dilute the radiolabeling 
mixture prior to the injection onto the semi-preparative 
HPLC column for purification gave better separation of 
[11C]4a from its desmethylated precursor 5.29-31,33  
The radiosynthesis was performed in a home-built 
automated multi-purpose [11C]-radiosynthesis module, 
allowing measurement of specific radioactivity during 
synthesis.34-36 This [11C]-radiosynthesis module includes 
the overall design of the reaction, purification and 
reformulation capabilities of the prototype system. In 
addition, [11C]-tracer specific activity (SA, GBq/µmol at 
EOB) can be automatically determined prior to product 
delivery for compounds purified by the HPLC-portion 
of the system.36,37 The SA was in a range of 370-1110 
GBq/µmol at EOB. The SA for the [11C]-tracers 
synthesized by [11C]-methylation with [11C]CH3OTf in 
our PET chemistry facility is depended on two parts: 1) 
carrier from the cyclotron consisted of the [11C]-gas 
irradiation target system, and 2) carrier from the 
[11C]CH3OTf system, [11C]-radiolabeled precursor or 
called [11C]-radiolabeled methylating reagent. If we can 
eliminate 12C carrier-added as much as possible, then 
we will be able to achieve higher SA. The [11C]-gas 
target we used is the Siemens RDS-111 Eclipse 
cyclotron [11C]-gas target. The technical trick to 
produce high SA [11C]CO2 is we will usually do 2-3 
times pre-burn with the same beam current and short 
time like 10 min before production run. This pre-burn 
will warm up the cyclotron and eliminate significant 
amount of 12C carrier-added in the cyclotron [11C]-gas 
target. The [11C]CH3OTf production system we used is 
an Eckert & Ziegler Modular Lab C-11 Methyl 
Iodide/Triflate module, convenient gas phase 
bromination of [11C]methane and production of 
[11C]CH3OTf, a ‘dry’ method using Br2 different with 
other ‘dry’ method using I2 and ‘wet’ method using 
LiAlH4 and HI. Our system will have much less 12C 
carrier-added in comparison with other ‘dry’ method 
and ‘wet’ method.25  
Chemical purity and radiochemical purity were 
determined by analytical HPLC.38 The chemical purity 
of the precursor 5 and reference standard 4a was >93%. 
The radiochemical purity of the target tracer [11C]4a 
was >99% determined by radio-HPLC through γ-ray 
(PIN diode) flow detector, and the chemical purity of 
[11C]4a was >90% determined by RP HPLC through 
UV flow detector. A C-18 Plus Sep-Pak cartridge 
instead of rotatory evaporation was used for purification 
and isolation process to significantly improve the 
chemical purity of the tracer solution.29-31,38  In this 
study, the Sep-Pak purification further increased the 
chemical purity >10%.29-31   
The experimental details and characterization data for 
compounds 1-5 and for the tracer [11C]4a are given.39 
In summary, a multi-step synthetic route with moderate 
to high yields for the synthesis of the precursor N-
desmethyl-CX-6258, reference standard CX-6258 and 
target tracer [11C]CX-6258 has been developed. An 
automated self-designed multi-purpose [11C]-
radiosynthesis module for the synthesis of [11C]CX-
6258 has been built, featuring the measurement of 
specific activity by the on-the-fly technique. The 
radiosynthesis employed N-[11C]methylation 
radiolabeling on amine nitrogen position of the 
precursor. Radiolabeling procedures incorporated 
efficiently with the most commonly used 
[11C]methylating agent, [11C]CH3OTf, produced by gas-
phase production of [11C]methyl bromide ([11C]CH3Br) 
from our laboratory. The target tracer was isolated and 
purified by a semi-preparative RP HPLC combined with 
SPE procedure in high radiochemical yield, 
radiochemical purity and chemical purity, short overall 
synthesis time, and high specific activity. These 
chemistry results warrant further biological evaluation 
of [11C]CX-6258 as a new PET agent for imaging of 
Pim kinases in cancer. 
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1H), 7.29-7.25 (m, 2H), 6.88, 6.81 (s+s, 1H), 3.73-
3.35 (m, 8H), 1.88 (br m, 1H), 1.61 (br m, 1H), 1.39 
(s, 9H). LC-MS (ESI, m/z): Calcd for C22H26N2O5Na 
([M+Na]+) 421.2, found 421.1. 
(e) (E)-3-(5-((5-Chloro-2-oxoindolin-3-
ylidene)methyl)furan-2-yl)benzoic acid (3): To a 
stirred suspension of compound 1 (1.5 g, 6.94 mmol) 
and 5-chlorooxindole (1.4 g, 8.33 mmol) in anhydrous 
EtOH (20 mL) was added piperidine (0.82 mL, 8.33 
mmol) dropwise under N2 atomsphere. After the 
reaction mixture was heated and stirred at 35 οC for 4 
h, it was allowed to stir at RT overnight. The solid was 
collected by filtration, washed with cold EtOH and 
hexanes to afford compound 3 as an orange solid (1.78 
g, 70%). 1H NMR (DMSO-d6): δ 13.19 (br s, 1H), 
10.72 (s, 1H), 8.51 (s, 1H), 8.45 (s, 1H), 8.17 (d, J = 
6.5 Hz, 1H), 8.00 (d, J = 6.0 Hz, 1H), 7.68 (s, 1H), 
7.49 (s, 2H), 7.41 (s, 1H), 7.32 (d, J = 7.0 Hz, 1H), 
6.91 (d, J = 7.0 Hz, 1H). LC-MS (ESI, m/z): Calcd for 
C20H11ClNO4 ([M-H]-) 364.0, found 364.0. 
(f) (E)-5-Chloro-3-((5-(3-(4-methyl-1,4-diazepane-1-
carbonyl)phenyl)furan-2-yl)methylene)indolin-2-one 
(CX-6258, 4a): Method A. To a stirred suspension of 
compound 2a (90 mg, 0.29 mmol) and 5-
chlorooxindole (51 mg, 0.30 mmol) in anhydrous 
EtOH (3 mL) was added piperidine (0.1 mL, 1.0 
mmol) dropwise under N2 atomsphere. After the 
reaction mixture was heated at reflux for 5 h, the 
solvent was removed in vacuo. The residual was 
purified with preparative TLC plate solid with 
CH2Cl2/MeOH (10:1) as eluent to afford compound 4a 
as an orange solid (59 mg, 44%).1H NMR (DMSO-
d6): δ 10.74 (s, 1H), 8.53 (s, 1H), 8.03 (d, J = 8.0 Hz, 
1H), 7.94 (s, 1H), 7.61 (t, J = 8.0 Hz, 1H), 7.50 (s, 
2H), 7.44-7.42 (m, 2H), 7.33 (d, J = 8.0 Hz, 1H), 6.92 
(d, J = 8.5 Hz, 1H), 3.64-3.63 (m, 2H), 3.41-3.38 (m, 
2H), 2.65 (br m, 1H), 2.55 (br m, 1H), 2.51-2.47 (m, 
2H), 2.29, 2.18 (s+s, 3H), 1.88 (br m, 1H), 1.73 (br m, 
1H). LC-MS (ESI, m/z): Calcd for C26H25ClN3O3 
([M+H]+) 462.2, found 462.2. Method B. To a stirred 
solution of compound 3 (150 mg, 0.41 mmol) in 
anhydrous DMF (4 mL) was added CDI (133 mg, 0.82 
mmol) under N2 atmosphere. After the mixture was 
stirred at RT overnight, N-methylhomopiperazine 
(0.13 mL, 1.04 mmol) was added. The reaction 
mixture was stirred for 24 h. Water (12 mL) was 
added to quench the reaction, and the mixture was 
stirred for 1 h. The precipitate was collected by 
filtration, washed with water, dried in vacuo. The 
crude product was purified with preparative TLC 
plates with CH2Cl2/MeOH (25:3) as eluent to afford 
compound 4a as an orange solid (148.4 mg, 78%). 
Analytical data was identical with Method A.  
(g) tert-Butyl (E)-4-(3-(5-((5-chloro-2-oxoindolin-3-
ylidene)methyl)furan-2-yl)benzoyl)-1,4-diazepane-1-
carboxylate (4b): Method A. To a stirred suspension 
of compound 2b (100 mg, 0.25 mmol) and 5-
chlorooxindole (44 mg, 0.26 mmol) in anhydrous 
EtOH (2.5 mL) was added piperidine (0.1 mL, 1.0 
mmol) dropwise under N2 atomsphere. After the 
reaction mixture was heated at reflux for 5 h, the 
solvent was removed in vacuo. The residual was 
purified with preparative TLC plate solid with 
CH2Cl2/MeOH (50:3) as eluent to afford compound 
4b as an orange solid (137 mg, 64%). 1H NMR 
(CDCl3): δ 8.77 (s, 1H), 8.58, 8.55  (s+s, 1H), 7.82 (d, 
J = 7.0 Hz, 1H), 7.51 (quin, J = 7.5 Hz, 1H), 7.38-7.34 
(m, 2H), 7.17 (dd, J = 8.0, 17.0 Hz, 1H), 6.82, 6.77 
(d+d, J = 8.0, 8.0 Hz, 1H), 3.83 (br m, 1H), 3.74 (t, J 
= 5.5 Hz, 1H), 3.66 (br m, 1H), 3.57-3.39 (m, 5H), 
1.99 (br m, 1H), 1.73 (m, 1H), 1.50 (s, 9H). LC-MS 
(ESI, m/z): Calcd for C30H29ClN3O5 ([M-H]-) 546.2, 
found 546.2. Method B. To a stirred solution of 
compound 3 (200 mg, 0.55 mmol) in anhydrous DMF 
(5 mL) was added CDI (178 mg, 1.1 mmol) under N2 
atmosphere. After the mixture was stirred at RT 
overnight, 1-Boc-hexahydro-1,4-diazapine (0.27 mL, 
1.38 mmol) was added. The reaction mixture was 
stirred for 24 h. Water (15 mL) was added to quench 
the reaction, and the mixture was stirred for 1 h. The 
precipitate was collected by filtration, washed with 
water, dried in vacuo. The crude product was purified 
with preparative TLC plates with CH2Cl2/MeOH 
(50:3) as eluent to afford compound 4b as an orange 
solid (300 mg, 79%). Analytical data was identical 
with Method A.  
(h) (E)-3-((5-(3-(1,4-Diazepane-1-
carbonyl)phenyl)furan-2-yl)methylene)-5-
chloroindolin-2-one (N-desmethyl-CX-6258, 5): To a 
stirred solution of compound 4b (80 mg, 0.15 mmol) 
in CH2Cl2 (1 mL) was added TFA (0.2 mL) dropwise 
at 0 οC. After the reaction mixture was stirred for 4 h, 
the solvent was removed in vacuo. The crude product 
was washed with Et2O to afford compound 5 TFA salt 
as an orange solid (54 mg, 66%). 1H NMR (DMSO-
d6): δ 10.76 (s, 1H), 9.00 (s, 2H), 8.54 (s, 1H), 8.06 (d, 
J = 7.5 Hz, 1H), 7.97 (s, 1H), 7.66 (t, J = 7.0 Hz, 1H), 
7.55-7.42 (m, 2H), 7.34 (d, J = 7.5 Hz, 1H), 6.93 (d, J 
= 8.0 Hz, 1H), 3.86-3.63 (m, 3H), 3.45-3.44 (m, 2H), 
3.25 (m, 3H), 2.07-1.95 (m, 2H). LC-MS (ESI, m/z): 
Calcd for C25H23ClN3O3 ([M+H]+) 448.1, found 448.1. 
The free base was prepared by addition of compound 
5 TFA salt in water and basified with NH4OH to pH 
10. The mixture was extracted with CH2Cl2. The
combined organic layer was washed with water, brine 
and dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to afford an orange solid for 
labelling.    
(i) (E)-5-Chloro-3-((5-(3-(4-[11C]methyl-1,4-
diazepane-1-carbonyl)phenyl)furan-2-
yl)methylene)indolin-2-one ([11C]CX-6258, [11C]4a): 
[11C]CO2 was produced by the 14N(p,α)11C nuclear 
reaction in the small volume (9.5 cm3) aluminum gas 
target provided with the Siemens RDS-111 Eclipse 
cyclotron. The target gas consisted of 1% oxygen in 
nitrogen purchased as a specialty gas from Praxair, 
Indianapolis, IN. Typical irradiations used for the 
development were 55 µA beam current and 30 min on 
target.  The production run produced approximately 
45.5 GBq of [11C]CO2 at EOB. In a small reaction vial 
(5 mL), the precursor 5 (0.3-0.5 mg) was dissolved in 
DMSO (400 µL).  To this solution was added NaH (1 
mg). No carrier-added (high specific activity) 
[11C]CH3OTf that was produced by the gas-phase 
production method25 from [11C]CO2 through [11C]CH4 
and [11C]CH3Br with silver triflate (AgOTf) column 
was passed into the reaction vial at RT, until 
radioactivity reached a maximum (~2 min), and then 
the reaction vial was isolated and heated at 80 οC for 3 
min. The contents of the reaction vial were diluted 
with NaHCO3 solution (0.1 M, 1 mL), and injected 
onto the semi-preparative RP HPLC column with 3 
mL injection loop for purification. The product 
fraction was collected in a recovery vial containing 30 
mL water. The diluted tracer solution was then passed 
through a C-18 Sep-Pak Plus cartridge, and washed 
with water (5 mL × 4).  The cartridge was eluted with 
EtOH (1 mL × 2), followed by 10 mL saline, to 
release [11C]4a.  The eluted product was then sterile-
filtered through a sterile vented Millex-FG 0.2 µm 
filter, and collected into a sterile vial. Total 
radioactivity (4.6-8.2 GBq) was assayed and total 
volume (10-11 mL) was noted for tracer dose 
dispensing. The overall synthesis, purification and 
formulation time was 30-40 min from EOB.  
Retention times in the analytical HPLC system were: 
tR 5 = 3.38 min, tR 4a = 5.51 min, tR [11C]4a = 5.64 
min. Retention times in the semi-preparative HPLC 
system were: tR 5 = 5.83 min, tR 4a = 8.67 min, tR 
[11C]4a = 8.88 min. The radiochemical yield of 
[11C]4a was 40-50% decay corrected to EOB, based 
on [11C]CO2. 
